Altimmune (ALT) EV/EBITDA: History & Chart

Altimmune, Inc.(ALT)

Biotechnology · Gaithersburg, MD

$2.67-0.06 (-2.38%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.

Gaithersburg, MD

57 employees

altimmune.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jerome Benedict Durso

View full financials

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Altimmune, Inc. (ALT)	$519.25M	N/A	N/A	N/A	N/A
Crescent Biopharma, Inc. (CBIO)vs ›	$517.79M	N/A	N/A	N/A	N/A
Allogene Therapeutics, Inc. (ALLO)vs ›	$517.73M	N/A	N/A	N/A	N/A
Evolus, Inc. (EOLS)vs ›	$491.93M	N/A	N/A	N/A	N/A
NeoGenomics, Inc. (NEO)vs ›	$491.55M	N/A	74.72x	37.71x	26.88x
Delcath Systems, Inc. (DCTH)vs ›	$547.86M	N/A	144.36x	144.36x	144.36x
Bright Minds Biosciences Inc. (DRUG)vs ›	$487.30M	N/A	N/A	N/A	N/A
Arvinas, Inc. (ARVN)vs ›	$481.33M	N/A	N/A	N/A	N/A
Contineum Therapeutics, Inc. (CTNM)vs ›	$478.54M	N/A	5.88x	17.52x	17.52x
CytomX Therapeutics, Inc. (CTMX)vs ›	$561.67M	N/A	13.55x	10.69x	10.69x

NAME

MARKET CAP

EV/EBITDA RATIO

TTM

Altimmune, Inc. (ALT)

$519.25M

N/A

Crescent Biopharma, Inc. (CBIO)vs ›

$517.79M

N/A

Allogene Therapeutics, Inc. (ALLO)vs ›

$517.73M